Search research articles
Contact Us
Filters
Showing results (11-20 of 15) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 15 results.
Cancer Prevention Research (Philadelphia, Pa.)
|
August 18, 2011
Methyl selenocysteine: single-dose pharmacokinetics in men
James R Marshall, Clement Ip, Karen Romano, et al.
Oral Oncology
|
July 13, 2013
A phase I trial of aminolevulinic acid-photodynamic therapy for treatment of oral leukoplakia
Stuart J Wong, Bruce Campbell, Becky Massey, et al.
Cancer Prevention Research (Philadelphia, Pa.)
|
February 7, 2012
Soy isoflavone supplementation for breast cancer risk reduction: a randomized phase II trial
Seema A Khan, Robert T Chatterton, Nancy Michel, et al.
The Oncologist
|
February 8, 2021
Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma
Dickran Kazandjian, Alexander Dew, Elizabeth Hill, et al.
JAMA Oncology
|
September 16, 2021
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial
Dickran Kazandjian, Elizabeth Hill, Alexander Dew, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 15) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 15 results.
Cancer Prevention Research (Philadelphia, Pa.)
|
August 18, 2011
Methyl selenocysteine: single-dose pharmacokinetics in men
James R Marshall, Clement Ip, Karen Romano, et al.
Oral Oncology
|
July 13, 2013
A phase I trial of aminolevulinic acid-photodynamic therapy for treatment of oral leukoplakia
Stuart J Wong, Bruce Campbell, Becky Massey, et al.
Cancer Prevention Research (Philadelphia, Pa.)
|
February 7, 2012
Soy isoflavone supplementation for breast cancer risk reduction: a randomized phase II trial
Seema A Khan, Robert T Chatterton, Nancy Michel, et al.
The Oncologist
|
February 8, 2021
Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma
Dickran Kazandjian, Alexander Dew, Elizabeth Hill, et al.
JAMA Oncology
|
September 16, 2021
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial
Dickran Kazandjian, Elizabeth Hill, Alexander Dew, et al.
Page
of 2